Doxorubicin cellular pharmacokinetics plays no role in chemosensitizing effect of verapamil on Swiss-3T3 cells

Acta Pharmacologica Sinica

Volumn 17, Issue 5, 1996, Pages 402-406

  Wang, Nan ^a   Tang, Zhong Ming ^a   Zhang, Yang Pei ^a   Ding, Qing Ming ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

cultured tumor cells; doxorubicin; drug resistance; fibroblasts; pharmacokinetics; verapamil

Indexed keywords

DOXORUBICIN; RNA; VERAPAMIL;

ANIMAL CELL; ARTICLE; CELL LEVEL; CELL SPECIFICITY; CELL STRAIN 3T3; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG RETENTION; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; SENSITIZATION;

3T3 CELLS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DOXORUBICIN; DRUG INTERACTIONS; GENE EXPRESSION; GENES, MDR; HUMANS; MICE; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0029765784     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
2. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-99.
3. Beck WT. Modulators of P-glycoprotein-associated multidrug resistance. In: Ozols RF, editor. Molecular and clinical advances in anticancer drug resistance. Boston: Kluwer Academic Publishers, 1991: 151-70.
4. 2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression. Br J Cancer 1991; 64: 1011-8.
5. Slovak ML, Hoeltge GA, Dalton WS, Trent, JM. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res 1988; 48: 2793-7.
6. Coley HM, Workman P, Twentyman PR. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression. Br J Cancer 1991; 63: 351-7.
7. Delvaeye M, Verovski V, De Neve W, Storme G. DNA breakage, cytotoxicity, drug accumulation and retention in two human ovarian tumor cell lines AZ224 and AZ364 treated with adriamycin, modulated by verapamil. Anticancer Res 1993; 13: 1533-8.
8. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986; 261: 15544-9.
9. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-42.
10. Wang N, Zhao DH, Sheng BH. A program for analysis of dose-response relationship with logistic model. Acta Pharmacol Sin 1990; 11: 187-92.
11. Radel S, Bankusli I, Mayhew E, Rustum YM. The effects of verapamil and a tiapamil analogue, DMDP, on adriamycin-induced cytotoxicity in P388 adriamycin-resistant and -sensitive leukemia in vitro and in vivo. Cancer Chemother Pharmacol 1988; 21: 25-30.
12. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
13. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
14. Sambrook J, Fritsch EF, Maniatis T. editors. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989: 7.54.
15. Cano-Gauci DF, Riordan JR. Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation. Biochem Pharmacol 1987; 36: 2115-23.